


This listing of claims will replace all prior versions of claims in the application.

Claims 1-11. (cancelled)

Claim 12. (new) A compound of Formula (I)




wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

U is hydrogen, halogen, an alkyl, heteroalkyl-, hetero-cycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

G-E is selected from the following groups,



wherein R' is F or a C<sub>1</sub>-C<sub>3</sub> alkyl group or G-E is part of an optionally substituted phenyl ring,

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub>-alkyl-, a C<sub>1</sub>-C<sub>4</sub>-alkenyl-, a C<sub>1</sub>-C<sub>4</sub>-alkynyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-group,

L-V-W is a group of formula CH=CH-CH, CH<sub>2</sub>-CH<sub>2</sub>-CH or CH<sub>2</sub>-CH=C, wherein the double bonds may be cis or trans isomers,

n is 0 or 2,



X is oxygen or a group of the formula  $\text{NR}^2$ , wherein  $\text{R}^2$  is hydrogen, an alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or heteroarylalkyl-group and

$\text{R}^3$  and  $\text{R}^4$  independently from each other represent hydrogen,  $\text{C}_1$ - $\text{C}_4$ -alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

Claim 13. (new) A compound of claim 12, wherein A is a group of the formula  $-\text{C}(\text{CH}_3)=\text{CHR}^5$  or  $-\text{CH}=\text{CHR}^5$ , wherein  $\text{R}^5$  is a heteroaryl- or a heteroarylalkyl group.

Claim 14. (new) A compound of claim 12, wherein A is a group of formula (II) or (III)



wherein Q is sulphur, oxygen or  $\text{NR}^7$ , wherein  $\text{R}^7$  is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl or  $\text{C}_1$ - $\text{C}_4$  heteroalkyl, z is Nitrogen or CH and  $\text{R}^6$  is  $\text{OR}^B$ ,  $\text{NHR}^8$ ,  $\text{C}_1$ - $\text{C}_4$  alkyl,  $\text{C}_1$ - $\text{C}_4$  alkenyl,  $\text{C}_1$ - $\text{C}_4$  alkynyl or  $\text{C}_1$ - $\text{C}_6$  heteroalkyl, wherein  $\text{R}^8$  is hydrogen,  $\text{C}_1$ - $\text{C}_4$  alkyl or  $\text{C}_1$ - $\text{C}_4$  heteroalkyl.

Claim 15. (new) A compound of claim 12, wherein X is oxygen or NH.

Claim 16. (new) A compound of claim 12, wherein R<sup>1</sup> is methyl or ethyl.

Claim 17. (new) A compound of claim 12, wherein R<sup>3</sup> and R<sup>4</sup> are each methyl.

Claim 18. (new) A compound of claim 12, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.

Claim 19. (new) A compound of claim 14, wherein z is CH and Q is sulphur or oxygen.

Claim 20. (new) A compound of claim 14, wherein R<sup>6</sup> is methyl, CH<sub>2</sub>OH or CH<sub>2</sub>NH<sub>2</sub>.

Claim 21. (new) A pharmaceutical composition comprising a compound of claim 1 or a pharmacologically acceptable salt, a solvate, a hydrate or a prodrug thereof, and optionally carriers and/or adjuvants and/or diluents.

Claim 22. (new) A method for treating a patient suffering from or susceptible to cancer, comprising administering to the patient a compound of claim 1.

W. Richter et al.  
Express Mail Label EV 654380630US  
Page 5

Claim 23. (new) The method of claim 22 wherein the patient is identified as suffering from cancer and selected for treatment of cancer, and the compound is administered to the identified and selected patient.